Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ...

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer is acquiring a pharma company that has multiple GLP-1 drugs in development. The deal may cost the company up to $7.3 billion, which is a move Pfizer can afford to make given its strong ...

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...